Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shuangdong (also known as Shuangdong Granules) is a Traditional Chinese Medicine (TCM) candidate developed by Guizhou Remote Pharmaceutical Co., Ltd. for the treatment of acute uncomplicated lower urinary tract infections (uLUTI). In TCM terminology, it is indicated for the "Damp-heat in the lower burner" syndrome, aiming to clear heat, resolve dampness, and alleviate symptoms such as urinary frequency, urgency, and dysuria. The formulation has advanced to Phase 3 clinical trials in China, where it is being evaluated for its efficacy and safety compared to standard treatments. As a multi-herb product, its therapeutic effects are attributed to the synergistic action of various phytochemicals that provide anti-inflammatory and diuretic benefits.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shuangdong.